van der Aa, D. C.
Gisbertz, S. S.
Anderegg, M. C. J.
Lagarde, S. M.
Klaassen, R.
Meijer, S. L.
van Dieren, S.
Hulshof, MCCM
Bergman, JJGHM
Bennink, R. J.
van Laarhoven, H. W. M.
van Berge Henegouwen, M. I.
Article History
Accepted: 9 June 2023
First Online: 1 July 2023
Declarations
:
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Bergman is a consultant for Boston Scientific, Cook Medical, and Medtronic and has received research funding from Aqua Medical, Fuji Film, Olympus Endoscopy, Pentax Medical, and Medtronic. Van Laarhoven has served as a consultant for BMS, Celgene, Lilly, and Nordic and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips, Roche, and Servier. Van Berge Henegouwen reports research grants from Stryker, in addition to consulting fees from Medtronic, Mylan BBraun, and Johnson and Johnson. The remaining authors have no conflicts of interest to report.